Login to Your Account

Odonate prices, raises $150M, as Denali upsizes IPO

By Marie Powers
News Editor

Thursday, December 7, 2017

Chemotherapeutic developer Odonate Therapeutics Inc. extended the 2017 biopharma IPO window, offering 6.25 million common shares at $24 apiece to raise $150 million.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription